KCNA3 and COVID-19: In addition, the use of pharmacological treatments for COVID‐19, such as antimalarial agents (hydroxychloroquine/chloroquine) and anti‐viral agents (lopinavir/ritonavir), has been shown to further prolong the QTc interval through inhibition of the hERG‐potassium channel and inhibition of the enzyme cytochrome 450, thereby increasing the risk of QT‐related life‐threatening ventricular arrhythmias, particularly TdP.34